HopeStage
Back to all studies
RecruitingNCT05922878

ALTO-300 or placebo added to antidepressant treatment for major depression

About this titleRead the official source — NCT05922878

Researchers are comparing ALTO-300 and placebo to find out how the approaches affect depression symptoms in adults with depression.

Medication studyAges 18–70United States
The study in practice

Understand this study

What is this study about?

Researchers are comparing ALTO-300 and placebo to find out how the approaches affect depression symptoms in adults with depression.

Who could participate?

This study is for people with depression. Listed age limits: 18 years to 70 years. Other eligibility criteria apply.

What will I do during this study?

Depending on your group, you take an ALTO-300 or matching placebo (an inactive comparison treatment) capsule each evening from Day 1 to Day 42. The protocol also describes an open-label ALTO-300 period of up to eight weeks for participants admitted to that phase.

Listed locations
Phoenix and 74 more locationsSee all locations and recruitment
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.

Get this study by email

HopeStage may email me about this study.
Loading the security check...

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateStarted: June 8, 2023
Recruitment status
Recruiting
Enrollment listed in the registry
325
Sponsor
Alto Neuroscience
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
United States
Age range
From 18 Years to 70 Years
Official registry ID
NCT05922878
Official title
Show the full official title

A Randomized, Double-Blind, Placebo-Controlled Study of ALTO-300 With an Open-Label Extension in Adults With Major Depressive Disorder

Recruitment & locations

Currently recruiting

Phoenix · Yuma · Rogers

64 more locations
  • Bellflower
  • Carlsbad
  • Glendale
  • Lafayette
  • Los Angeles
  • Mather
  • Mission Viejo
  • Moorpark
  • Temecula
  • Colorado Springs
  • Denver
  • Evergreen
  • Norwalk
  • Clermont
  • Miami Gardens
  • Miami Lakes
  • Okeechobee
  • Tampa
  • West Palm Beach
  • Fayetteville
  • Savannah
  • Snellville
  • Stone Mountain
  • Blackfoot
  • Boise
  • Chicago
  • Wichita
  • Marrero
  • Monroe
  • Worcester
  • Mankato
  • Minneapolis
  • Hattiesburg
  • Jackson
  • Creve Couer
  • St Louis
  • Omaha
  • Las Vegas
  • Albuquerque
  • New York
  • Rochester
  • Staten Island
  • Hickory
  • Rose Hill
  • Winston-Salem
  • Cincinnati
  • Oklahoma City
  • Allentown
  • Media
  • Moosic
  • Austin
  • Conroe
  • Dallas
  • Fort Worth
  • Houston
  • Missouri City
  • Plano
  • Richmond
  • San Marcos
  • Stephenville
  • Clinton
  • Provo
  • Fairfax
  • Roanoke

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

What is this study about?

Researchers are comparing ALTO-300 and placebo to find out how the approaches affect depression symptoms in adults with depression.

Who is behind this study?

The study sponsor is Alto Neuroscience.

Does this study involve medication?

Yes. The study involves medication, including ALTO-300 and Placebo.

Who can participate?

This study is for people with depression. Listed age limits: 18 years to 70 years. Other eligibility criteria apply.

Is this study still recruiting?

The registry lists this study as recruiting.

Want to explore more studies?

Explore studies